Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
暂无分享,去创建一个
Christopher McCabe | Richard Edlin | Klemens Wallner | R. Edlin | C. McCabe | P. Hall | Peter Hall | K. Wallner
[1] M. Toumi,et al. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts , 2011, BMC health services research.
[2] Christopher McCabe,et al. Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help? , 2013, PharmacoEconomics.
[3] C. McCabe,et al. Funding the Unfundable , 2012, PharmacoEconomics.
[4] Karl Claxton,et al. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] R. Edlin,et al. Access with Evidence Development Schemes , 2012, PharmacoEconomics.
[6] D. Cameron,et al. Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer , 2010, PharmacoEconomics.
[7] Andrew Briggs,et al. Value based pricing for NHS drugs: an opportunity not to be missed? , 2008, BMJ : British Medical Journal.
[8] Norman Daniels,et al. Accountability for reasonableness , 2000, BMJ : British Medical Journal.
[9] Louis P Garrison,et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. , 2010, Health policy.
[10] N. Daniels,et al. Accountability for reasonableness. , 2000, BMJ.
[11] Jon Sussex,et al. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold , 2013 .
[12] W. Gregory,et al. Expected Net Present Value of Sample Information , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.